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Abstract
Celecoxib is a selective inhibitor of cyclooxy-
genase-2 (COX-2) that is a critical factor in car-
cinogenesis, but precise mechanism of its action  
remains to be elucidated. Here we evaluated the  
inhibitory effect of celecoxib on cell growth of human  
oral squamous cell carcinoma (OSCC) YD-10B, 
which was established to be used as in vitro OSCC  
model, and identified celecoxib-regulated protein by  
proteomics techniques. Celecoxib (IC50 = 37 µM) 
inhibited the growth of YD-10B cells with the  
decrease of COX-2 protein expression. Its inhibition  
could be linked in the arrest of G1 phase with  
increased levels of p27 protein, a specific CDK  
inhibitor. Using proteomics, the 10- to 20-fold  
increase of heterogeneous nuclear ribonuclear pro -
tein C (hnRNP C), which has been suggested to be  
related with the translation of p27 mRNA, was  
observed in celecoxib-treated YD-10B cells. In  
summary, celecoxib has a potential to induce the  
protein expression of hnRNP C and its increase  
subsequently induce the translation of p27 mRNA, 
which trigger the inhibition of cell growth via  
p27-regulated cell cycle arrest in YD-10B cells. In  
addition, YD-10B cells could be useful to study the  
pathological mechanism of OSCC. 
Keywords: carcinoma, squamous cell; celecoxib; 
cell cycle; cyclin-dependent kinase inhibitor p27; cy-
clooxygenase 2 inhibitors; heterogeneous-nuclear ri-
bonucleoprotein C 
Introduction
Oral malignancy, the commonest form of which is 
squamous cell carcinoma (SCC), constitutes a major 
worldwide health problem (Jemal et al., 2003). 
Moreover, despite curative therapy for oral squa-
mous cell carcinoma (OSCC), patients may ex-
perience debilitating changes in appearance, spee-
ch, swallowing, and breathing. 
    Chemoprevention appears to be a promising 
strategy for the inhibition of carcinoma before the 
development of invasive tumors, but current stra-
tegies are far from satisfactory, primarily due to the 
significant toxicity associated with these approaches. 
In the search for agents with potentials to prevent or 
delay the onset of cancer, it has become apparent 
that cyclooxygenase-2 (COX-2) is a promising thera-
peutic target (Fosslien et al., 2000; Hayashi et al., 
2001; Sirica et al., 2001; Nzeako et al., 2002; Mohan 
et al., 2003; Subbaramaiah et al., 2003). Epi-
demiological studies and clinical observation sug-
gest that the regular consumption of nonsteroidal 
anti-inflammatory drugs (NSAIDs) may reduce the 
risk of developing several types of human cancer by 
regulating the expression/activity of COX-2 (Fosslien 
et al., 2000; Hayashi et al., 2001; Sirica et al., 2001; 
Subbaramaiah et al., 2003). Recently many groups 
have reported that NSAIDs can suppress growth of 
human cancer cells, including those associated with 
head and neck carcinomas by inducing the cells to 
arrest at the G0/G1 or G2/M phase; often they induce 
apoptosis as well (Fosslien et al., 2000; Hayashi et 
al., 2001; Sirica et al., 2001; Nzeako et al., 2002; Wu 
et al., 2002). However, considering the report show-
ing that the anti-proliferative effects of NSAIDs on 
cancer cells are both dependent and independent on 
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the inhibition of COX-2 activity and prostaglandin 
synthesis (Gupta et al., 2001; Choi et al., 2004; 
Maier et al., 2004), the precise mechanism and in-
volvement of NSAIDs on the process of carcino-
genesis still remain to be elucidated.
    Celecoxib is a newly developed COX-2 inhibitor 
with significantly less toxicity. Recently, chemopre-
ventive activity of celecoxib in oral carcinoma cell 
has been reported showing that celecoxib signi-
ficantly delayed cell growth and reduced tumor 
volume in mice to which oral carcinoma cells were 
intradermal inoculated (Wang et al., 2002). In this 
report, no toxic effect was found by means of 
measurement of body weight loss and microscopic 
dissection of organs. Based on this report, here the 
inhibitory mechanism of celecoxib on the cell growth 
was evaluated to understand its functional mecha-
nism in OSCC. Especially, in this study, COX-2-over-
expressed OSCC (named YD-10B) was established 
and used. This was for evaluating whether YD-10B 
cells could be used as in vitro model of OSCC. In 
addition, proteins regulated by the treatment of 
celecoxib were identified by proteomics technolo-
gies. 
Materials and Methods
Establishment of cell lines and cell culture  
The surgical specimens utilized in this study were 
obtained from a patient (67 yr-old male with mod-
erately differentiated squamous cell carcinoma in 
tongue; no pathological nodal status; no clinical 
history for anti-cancer therapy). Tissues were trans-
ported in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with 10% fetal bo-
vine serum (FBS), 1 × 10-10 M cholera toxin, 0.4 
mg/ml hydrocortisone, 5 g/ml insulin, 5 g/ml trans-
ferrin, and 2 ×10-11 M triiodothyronine. Tissues were 
treated with trypsin and then the isolated cells were 
grown with a feeder layer composed of mitomycin 
C-treated NIH 3T3 fibroblasts. The cells were fed 
with a mixture of DMEM and Ham's nutrient mixture 
F12 at a 3:1 ratio, supplemented with 10% FBS, 1 ×
10-10 M cholera toxin, 0.4 mg/ml hydrocortisone, 5 
g/ml insulin, 5 g/ml transferrin, and 2 × 10-11 M 
triiodothyronine. All materials used in cell culture 
experiment were purchased from Life Technologies, 
Inc. (Grand island, NY). The cells were cultured in a 
humidified atmosphere of 5% CO2 at 37oC. Cells 
were subcultured twice a week by trypsinization for 1 
yr after initial cultivation, and the cell line was con-
sidered to be “established” after 40 such passages. 
In this experiment, we used the cell line between 
150 and 160 such passage. This carcinoma cell line, 
which was acquired from human tongues, was 
designated as the YD-10B cell line. The YD- 10B cell 
line exhibits frameshift p53 mutation. (Lee et al., 
2005)
Cell viability assay
Celecoxib (Pfizer, Groton, CN) was dissolved in 
DMSO (Sigma, Indianapolis, IN). Each treatment 
condition contained the same amount of DMSO. As 
DMSO modulates keratinocyte differentiation and 
proliferation, blank controls and solvent controls 
were also included to confirm that the DMSO had 
extended no such effects at the concentrations used 
in this study. The percentage of growth inhibition 
was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT, Sigma) assay. 
Oral carcinoma YD-10B cells was seeded, cultured 
onto a 96-well plate (2.0 × 103 cells/well) for 24 h, 
treated with various concentrations (1-100 M) of 
celecoxib, and incubated for an additional 3 days. 
Subsequently, 100 l of MTT at a concentration of 5 
mg/ml was added to each well, and cells were 
incubated for an additional 4-6 h. The supernatant 
was aspirated, and 100 l of DMSO was added to 
the wells in order to dissolve any precipitate present. 
The absorbance was then measured at a 
wavelength of 570 nm using an ELX800 reader 
(Bio-Tek Instruments, Inc., Winooski, VT). 
Cell cycle analysis
A total of 2.0  105 cells/well was plated onto 60 cm2 
dish, and incubated for 24 h. Celecoxib (37 M) was 
added to the wells, and then incubated for an 
additional 3 days. Cells were washed, pelleted, fixed 
with cold 100% ethanol for at least 30 min, and 
incubated at 37°C with 100 g/ml RNase A and 50 
g/ml propidium iodide in PBS for 30 min at room 
temperature. Samples were immediately analyzed 
by flow cytometry (Becton Dickinson, San Jose, CA). 
Cell cycle phase distribution was determined using 
Modfit software (Verity Software House, Topsham, 
ME).
Two-dimensional (2D) gel electrophoresis
Cells were washed well with PBS three times and 
homogenized in 0.5 ml sample buffer consisting of 
40 mM Tris, 7 M urea (Merck, Darmstadt, Germany), 
2 M thiourea (Sigma, St. Louis, MO), 4% CHAPS 
(3 - [ (3 -cho lamidopropy l )d imethy lammonio ] -1 - 
propane-sulfonate, Sigma), 60 mM 1,4-dithioerythri-
tol (Merck), 1 mM EDTA (Merck), 0.5% (v/v) IPG 
buffer with pI 4-7, 1 mM PMSF (phenylmethylsul-
fonyl fluoride, Sigma), and protease inhibitor cocktail 
tablet (Roche, Mannheim, Germany). The suspen-
sion was sonicated for approximately 30 s and 
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centrifuged at 12,000 × g for 1 h. The protein 
concentration of the supernatant was determined by 
the Coomassie blue method (Bradford et al., 1976). 
Samples (100 g) were applied on Immobiline 
Drystrip (pH 4-7, 18 cm, Amersham, Seoul, Korea). 
After the rehydration for 12 h, the proteins were 
focused at total 57,000 Vhrs. The second-dimen-
sional separation was performed on 12% poly-
acrylamide gels. After protein fixation with 40% 
methanol containing 5% phosphoric acid for 12 h, 
the gels were stained with silver staining kit 
(Amersham) according to manufacturer’s protocol. 
The molecular mass was determined by running 
standard protein markers at the right side of selected 
gels. The size markers (Gibco, Basel, Switzerland) 
covered the range 10-200 kDa. Isoelectric point (pI) 
values were used, as given by the supplier of the 
IPG strips. The gels were destained with water and 
scanned by GS-800 imaging densitomer (Bio-Rad). 
The images were analyzed by PDQuest software 
(Bio-Rad). Among ~ 800 proteins spots which were 
increased more than 10-fold after the treatment of 
celecoxib were decided to be identified.
Matrix-assisted laser adsorption ionization-time of 
flight mass spectrometry (MALDI-TOF MS) analysis
Two protein spots, which were increased more than 
10-fold after the treatment of celecoxib, were 
excised from the gels and destained with buffer 
containing 30 mM potassium ferrycyanide and 100 
mM sodium thiosulfate and washed with distilled 
water. The protein spots were then dehydrated in a 
SpeedVac for 10 min. Gel pieces were rehydrated in 
10 l (10 ng/ml) of sequencing grade trypsin solution 
(Promega, Madison, WI) in 25 mM ammonium bicar-
bonate buffer, pH 7.8, at 37oC overnight. After re-
moving the trypsin solution, the resulting peptides 
were extracted with 5 ml of 0.5% TFA containing 
50% ACN by sonication. Peptide extraction was 
done at room temperature for 40 min. The tryptic 
digested peptide samples (1 ml) were mixed with 
equal volumes of CHCA (5 mg/ml in 50% v/v ACN/ 
0.1% TFA) and loaded onto a target plate. MALDI- 
TOF mass spectra were obtained on a Voyager-DE 
STR mass spectrometer (Per-Spective Biosystems, 
Framingham, MA). Peptide matching and protein 
searches against the Swiss-Prot and NCBI data-
bases were performed using the ProFound program 
(http://prowl.rockefeller.edu/).
Immunoblotting analysis  
Proteins were extracted from the cells using a buffer 
containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 
0.1% SDS, 1% NP40, and 1  protease inhibitors 
(Roche Applied Science, Indianapolis, IN). Proteins 
(15 g) were separated by electrophoresis through a 
10% SDS polyacrylamide gel and then transferred 
onto a nitrocellulose membrane. The membrane was 
blocked in a blocking buffer (5% dry milk, 20 mM 
Tris-HCl (pH7.5), 100 mM NaCl, and 0.1% Tween 
20) for 2 h. The membrane was incubated for 2 h at 
room temperature with 1:1,000 diluted primary anti-
body. After washing three times for 15 min with 
blocking buffer, membranes were probed with 
1:2,000 diluted secondary antibodies for 1 h. The an-
tibodies used in this study were purchased from the 
Santa Cruz Biotechnology (Delaware Avenue, CA) 
with the exception of the anti-human -actin mono-
clonal antibody (Sigma). The membrane was wash-
ed three times for 15 min and developed with 
Western Blotting Luminol Reagents (Santa Cruz 
Biotechnology). The densities of bands were mea-
sured by Multi Gauge version 3.0 software (Fuji 
Photo Film Co., Ltd, Tokyo, Japan).
Results
Having established COX-2-overexpressing human 
OSCC YD-10B cells, we attempted to ascertain 
whether celecoxib, a COX-2-selective inhibitor, would 
inhibit the growth of oral cancer cells. When YD-10B 
cells were exposed to the continuous treatment of 
celecoxib at a concentration of 0-100 M, in the 
presence of serum, the cell growth was inhibited in a 
dose-dependent manner and IC50 of celecoxib on 
cell growth of YD-10B was 37 M (Figure 1). In the 
treatment of celecoxib (37 M), the protein ex-
pression level of COX-2 was dramatically decreased 
to 72% and 48% after 48 h and 72 h, respectively 
(Figure 2). 
Figure 1. Celecoxib-inhibited cell growth of YD-10B cells. Cells were 
seeded onto 96-well plates at 2.5 × 103 cells/well, and were treated 
with different concentrations of celecoxib. The percentages of growth 
inhibition were determined by MTT assay after 72 h of treatment. 
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    In order to determine whether the celecoxib- 
induced suppression of YD-10B cell growth was 
associated with cell cycle arrest, cell cycle distri-
bution was evaluated by flow cytometric analysis. 
Interestingly, as shown in Table 1, celecoxib signi-
ficantly induced a G0/G1 phase arrest, coupled with a 
concomitant decrease in the S phase. Next, the 
involvement of p21 and p27 in celecoxib-induced cell 
cycle arrest in YD-10B cells was evaluated by 
measuring the protein expression levels. As shown 
in Figure 3, celecoxib treatment induced protein 
levels of p27 (4-11 fold compared to control). 
Whereas the YD-10B cells express little or no p21 at 
baseline culture conditions, a minor increase in p21 
levels was observed after treatment with celecoxib 
(data not shown). 
    To identify celecoxib-regulated proteins in YD-10B 
cells, proteomics techniques were performed. Pro-
Figure 2. Celecoxib-inhibited protein expression of COX-2 in YD-10B 
cells. (A) Cells were incubated in the presence or absence of celecoxib 
(IC50 = 37 M). At different times, YD-10B cells were lysed and using 
these proteins, Western blot analysis was performed as described in 
Materials and Methods. -actin was used as an internal control. (B) 
The densities were normalized with that of -actin and normalized val-
ues were represented to % of control. 
Table 1. Effect of celecoxib on the cell cycle distribution in YD-10B cells. YD-10B cells were incubated in the presence or absence of
celecoxib (IC50 = 37 M) for 24, 48, and 72 h. Cells then were harvested, and the cell cycle profile was analyzed using flow cytometry
as described in Materials and Methods. Results were presented as mean (%) ± SD (n = 3). 
Phase of
cell cycle Vehicle
+ Celecoxib (37 M)
24 h 48 h 72 h
G1
S
G2
57.93 ± 4.91
32.90 ± 2.23
10.18 ± 4.10
73.74 ± 2.02 
18.73± 0.10 
 7.47± 2.202 
76.47± 1.88 
19.17 ± 0.43 
4.37 ± 1.44 
82.07 ± 0.59
13.01 ± 0.32
 4.50 ± 1.63
Figure 3. Celecoxib-induced protein expression of p27 in YD-10B 
cells. (A) Cells were incubated in the presence or absence of celecoxib 
(IC50 = 37 M). At different times, YD-10B cells were lysed and using 
these proteins, Western blot analysis was performed as described in 
Materials and Methods. -actin was used as an internal control. (B) 
The densities were normalized with that of -actin and normalized val-
ues were represented to % of control. 
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teins from cells treated with 37 M for 48 h were 
compared with those from control cells. Interestingly, 
of the spots investigated, two protein spots were 
increased more than 10-fold after the treatment of 
celecoxib (Figure 4). These spots were subjected to 
MALDI-TOF/MS and identified to heterogeneous 
nuclear ribonucleoprotein C (hnRNP C) isoform b 
(Table 2). The protein expression levels of hnRNP C 
were confirmed using specific antibody against 
hnRNP C. As shown in Figure 5, hnRNP C1/C2 ex-
pression was initially 3-fold induced by the treat-
ment of celecoxib (37 M) and it was 20-fold induced 
when cells were cultured with celecoxib for 72 h. 
Discussion
It has been shown that inhibition of COX-2 may 
cause growth arrest and reduced tumor formation in 
some human cancer, but the mechanism is not fully 
known. Recent report suggested that COX-2 could 
be a major target molecule showing a moderate to 
high COX-2 expression in 35 out of the 45 OSCC 
specimens (77.8%) (Pannone et al., 2004). Here, we 
used human oral squamous YD-10B carcinoma cells 
to study the growth inhibition and changes in cell 
cycle by the treatment of the selective COX-2 inhi-
bitor celecoxib. 
    Celecoxib inhibited the growth of YD-10B cells in 
a concentration-dependent manner with the decrea-
sed protein expression of COX-2. This is consistent 
with the report showing that celecoxib inhibits 
proliferation via prostaglandin E2 pathway (Wu et al., 
Figure 4. Partial image of 2D gel electrophoresis showing celecox-
ib-regulated proteins in YD-10B cells. Cells were incubated in the pres-
ence or absence of celecoxib (IC50 = 37 M). After 48 h, 2D gel elec-
trophoresis was performed using cell homogenates as described in 
Materials and Methods. Arrows (1 and 2) indicate proteins whose ex-
pressions were evaluated to be 10 and 20-fold higher in celecox-
ib-treated YD-10B cells compared to control, respectively. Numbers re-
fer to protein identities in Table 2. 
Table 2. Identification and expression levels of celecoxib-induced spot 1 and 2 in YD-10B cells. 
Spot 
No. Protein name Species
Accession 
number
No. of
matched 
peptides
Sequence 
coverage
(%)
Theoretical 
Mr (kDa)/pI
Measured 
Mr (kDa)/pI
MOWSE 
score
Expression
(vs. control)
1 heterogeneous nuclear 
ribonucleoprotein C
isoform b (hnRNP C)
Human 4758544 5 20 31.967/5.1 35/5.3  153 10-fold
increased
2 heterogeneous nuclear 
ribonucleoprotein C
isoform b (hnRNP C)
Human 4758544 6 25 31.967/5.1 35/5.3 2942 20-fold
increased
Figure 5. Celecoxib-induced protein expression of hnRNP C in 
YD-10B cells. (A) Cells were incubated in the presence or absence of 
celecoxib (IC50 = 37 M). At different times, YD-10B cells were lysed 
and using these proteins, Western blot analysis was performed as de-
scribed in Materials and Methods. -actin was used as an internal 
control. (B) The densities were normalized with that of -actin and nor-
malized values were represented to % of control. 
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2003). In addition, the results of flow cytometric 
analysis indicated that celecoxib induced G1-S 
arrest, with no significant effect on G2-M transition. 
Makitie et al. reported that inhibition of COX-2 by 
celecoxib markedly induces the expression of critical 
cell cycle-regulating proteins including p27 in OSCC 
(Makitie et al., 2003). In YD-10B cells, celecoxib 
dramatically induced the protein expression of p27. 
These results suggested that the celecoxib could 
induce the expression of p27, which consequently 
mediate the cell cycle arrest in G1-S. In addition, 
considering that YD-10B cells exhibit frameshift p53 
mutation, the inhibition of cell growth and induction 
of p27 by the treatment of a selective inhibitor of 
COX-2 celecoxib could be done in a p53-inde-
pendent manner. However, the further study should 
be carried out to elucidate the relationship between 
the mutation of p53 and the inhibition of cell growth 
and induction of p27 by the treatment of celecoxib in 
YD-10B cells.
    What proteins are involved in the inhibition of 
YD-10B cell growth by celecoxib? Using proteomics 
technologies, the up-regulation of hnRNP C protein 
was observed in this study. hnRNP C has been 
implicated in a variety of processes including spli-
cing, polyadenylation, and RNA turnover, and its 
intrinsic ability to wrap or fold relatively long lengths 
of pre-mRNA in a peripherally accessible manner is 
consistent with an RNA chaperonin-like activity 
(Herschlag et al., 1994; Herschlag et al., 1995). Fur-
thermore, the protein is preferentially phosphorylated 
during mitosis, suggesting that aspects of hnRNP C 
function are regulated during the cell cycle (Mayrand 
et al., 1993; Pinol Roma et al., 1993). Recent report 
showed that hnRNP C is not required for cell 
viability, but this protein may influence the rate 
and/or fidelity of one or more steps in mRNA bio-
genesis (Williamson et al., 2000). Interestingly, it has 
been suggested that hnRNP C is one of factors that 
bind to a U-rich sequence in the 5' untranslated 
region (5'UTR) of p27 mRNA, which is necessary for 
the translation of p27 mRNA, and consequently 
regulate the translation of p27 mRNA, suggesting 
that this interaction may be a target of antimitogenic 
signals (Millard et al., 2000). These data were also 
consistent with our data showing the induction of 
both p27 and hnRNP C in cell cycle-arrested YD- 
10B by the treatment of celecoxib. 
    In summary, celecoxib has a potential to induce 
the protein expression of hnRNP C and its increase 
subsequently induce the translation of p27 mRNA, 
which trigger the inhibition of cell growth via 
p27-regulated cell cycle arrest in YD-10B cells. Addi-
tionally, selective inhibition of COX-2 is a possible 
target for the therapeutic strategies to treat OSCC 
and established YD-10B cells could be useful to 
study the pathological mechanism of OSCC. 
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